FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 874 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR Trametinib Is a New Treatment Option for Rare Form of Ovarian... March 10, 2022 Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma December 18, 2024 Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... January 9, 2026 Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 Load more HOT NEWS What if we count all that still remains? Her Wedding Ceremony Was Interrupted By A Voice In The Back,... Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... Prostate Cancer
